Table 1.
Baseline Demographic and Clinical Characteristics by Xpert MTB/RIF Assay Result
| Overall | TB Negative | TB Positive | RS-TB | RR-TB | |
|---|---|---|---|---|---|
| Sample size, n (%) | 16 357 (100)a | 14 822 (90.6) | 1535 (9.4) | 1365 (88.9)b | 170 (11.0)b |
| Median age, years (IQR) | 36 (24–52) | 37 (24–52) | 35 (26–45) | 35 (26–45) | 35 (27–44) |
| Age <20 years | 2648 (16.2%) | 2481(16.7%) | 167 (10.9%) | 153 (11.2%) | 14 (8.2%) |
| Age >20 years | 13 709 (83.8%) | 12 341 (83.3%) | 1368 (89.1%) | 1212 (88.8%) | 156 (91.8%) |
| Male sex, n (%) | 9029 (55.2) | 8028 (54.2) | 1001 (65.2) | 886 (64.9) | 115 (67.6) |
| HIV status, n (%) | |||||
| Negative | 994 (6.1) | 29 (0.2) | 965 (62.8) | 843 (61.7) | 122 (71.7) |
| Positive | 135 (0.8) | 28 (0.2) | 107 (6.9) | 91 (6.7) | 16 (9.4) |
| Unknown | 15 228 (93.1) | 14 765 (99.6) | 463 (30.1) | 431 (31.6) | 32 (18.8) |
| WHO HIV stage, n (%) | |||||
| Stage I-III | 95 (67.4) | 7 (25.0) | 88 (82.2) | 76 (83.5) | 12 (75.0) |
| Stage IV | 12 (8.9) | 0 (0.0) | 12 (11.2) | 8 (8.8) | 4 (25.0) |
| Missing data | 28 (20.7) | 21 (75.0) | 7 (6.5) | 7 (7.7) | 0 (0.0) |
| TB category, n (%) | |||||
| New cases | … | … | 1289 (84.0) | 1217 (90.0) | 72 (42.4) |
| Retreatment | … | … | 234 (15.2) | 136 (10.0) | 98 (57.6) |
| After failure | … | … | 66 (4.2) | 35 (2.6) | 31 (18.2) |
| After relapse | … | … | 105 (6.8) | 65 (4.8) | 40 (23.5) |
| After LTFU | … | … | 63 (4.1) | 36 (2.7) | 27 (15.9) |
| Missing data | … | … | 12 (0.8) | 12 (0.9) | 0 (0.0) |
| Prior TB Episode, n (%) | |||||
| 0 | … | … | 1296 (84.4) | 1217 (89.9) | 79 (46.5) |
| 1 | … | … | 185 (12.0) | 121 (8.9) | 64 (37.6) |
| ≥2 | … | … | 42 (2.7) | 15 (1.1) | 27 (15.8) |
| Missing data | … | … | 12 (0.8) | 12 (0.9) | 0 (0.0) |
| Median (IQR) days from Xpert MTB/RIF result to treatment | … | … | 1.6 (0–6.2) | 1.1 (0–4.4) | 12 (3–62.4) |
| Positive sputum smear microscopy for AFB, n (%) |
715 (4.5) | 92 (0.6)c | 623 (40.5) | 499 (36.6) | 124 (72.9) |
Abbreviations: AFB, acid-fast bacilli; HIV, human immunodeficiency virus; IQR, interquartile range; LTFU, lost to follow-up; MDR, multidrug resistant; RR, rifampicin resistant; RS, rifampicin susceptible; S, success; TB, tuberculosis; WHO, World Health Organization.
aThis total excludes the indeterminate Xpert MTB/RIF assay results.
bThis percentage uses TB-positive cases (n = 1535) as a denominator.
cPossible contamination by non-tuberculous Mycobacteria.